Midazolam (Buccolam)
Indication
Status Epilepticus
MHRA Drug Safety Update - Buccal midazolam (Buccolam▼): new authorised medicine for paediatric use
Amber level 0
Brand:
Buccolam®
Nice TA:
Commissioning responsibility:
CCG
PbR excluded:
No
BNF chapter:
Central nervous system
Background
When an oral midazolam preparation is prescribed, a licensed product should be prescribed
Recommendation
LSCMMG Recommendation:
Amber level 0
Reason for decision:
Suitable for GP prescribing following recommendation/initiation by specialist
Supporting documents: